Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:17alpha-hydroxy-C21-steroid
go back to main search page
Accession:CHEBI:138141 term browser browse the term
Definition:Any C21-steroid carrying a hydroxy substituent at the 17alpha-position. Note that individual examples may have ring substituents at other positions and/or contain double bonds, aromatic A-rings, expanded/contracted rings etc., so the formula and mass may vary from that given for the generic structure.
Synonyms:related_synonym: Formula=C21H36O;   InChI=1S/C21H36O/c1-4-21(22)14-11-18-16-9-8-15-7-5-6-12-19(15,2)17(16)10-13-20(18,21)3/h15-18,22H,4-14H2,1-3H3/t15?,16?,17?,18?,19?,20?,21-/m1/s1;   InChIKey=JSIVWCLRCGAVHN-ILZKQPLKSA-N;   SMILES=C1CCCC2C1(C3C(CC2)C4C(CC3)([C@](CC4)(CC)O)C)C;   a 17alpha-hydroxy-C21-steroid
 xref: MetaCyc:17a-hydroxy-C21-steroids



show annotations for term's descendants           Sort by:
 
11-deoxycortisol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor multiple interactions ISO Cortodoxone binds to and results in increased activity of AR protein mutant form CTD PMID:11956172 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Cyp11b2 cytochrome P450, family 11, subfamily b, polypeptide 2 increases metabolic processing
affects metabolic processing
ISO CYP11B1 protein results in increased metabolism of Cortodoxone
CYP11B1 protein affects the metabolism of Cortodoxone
CTD PMID:15522937 PMID:15780661 PMID:15985365 PMID:16030167 PMID:16054388 More... NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
JBrowse link
G Cyp11b3 cytochrome P450, family 11, subfamily b, polypeptide 3 increases metabolic processing
affects metabolic processing
ISO CYP11B2 protein results in increased metabolism of Cortodoxone
CYP11B2 protein affects the metabolism of Cortodoxone
CTD PMID:15743198 PMID:19900470 NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 affects binding ISO Cortodoxone binds to NR3C1 protein CTD PMID:15705660 NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
JBrowse link
G Nr3c2 nuclear receptor subfamily 3, group C, member 2 increases activity ISO Cortodoxone results in increased activity of NR3C2 protein CTD PMID:15780662 NCBI chr19:30,715,648...31,059,885
Ensembl chr19:30,715,648...31,059,885
JBrowse link
17alpha-hydroxypregnenolone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 affects chemical synthesis
affects metabolic processing
decreases acetylation
multiple interactions
increases metabolic processing
ISO CYP17A1 protein affects the chemical synthesis of 17-alpha-Hydroxypregnenolone
CYP17A1 protein affects the metabolism of 17-alpha-Hydroxypregnenolone
CYP17A1 protein results in decreased acetylation of 17-alpha-Hydroxypregnenolone
[[abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone; [CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone; [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Venlafaxine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]
CTD PMID:15562394 PMID:16030167 PMID:17194026 PMID:29100959 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
JBrowse link
17alpha-hydroxyprogesterone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions ISO 17-alpha-Hydroxyprogesterone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein] CTD PMID:29782964 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Ar androgen receptor increases activity
multiple interactions
ISO 17-alpha-Hydroxyprogesterone results in increased activity of AR protein
17-alpha-Hydroxyprogesterone inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]
CTD PMID:21543282 PMID:33049310 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 multiple interactions EXP [Diethylstilbestrol results in decreased expression of CYP11A1 protein] which results in decreased abundance of 17-alpha-Hydroxyprogesterone CTD PMID:23873838 NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 affects abundance
increases metabolic processing
multiple interactions
affects metabolic processing
affects chemical synthesis
ISO CYP17A1 protein affects the abundance of 17-alpha-Hydroxyprogesterone
CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone
[[abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone; [CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone; [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone]; TNF protein inhibits the reaction [CYP17A1 protein affects the metabolism of 17-alpha-Hydroxyprogesterone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Venlafaxine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone]
CYP17A1 protein affects the chemical synthesis of 17-alpha-Hydroxyprogesterone
CTD PMID:16030167 PMID:17194026 PMID:21427057 PMID:29100959 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO 17-alpha-Hydroxyprogesterone binds to and results in increased activity of ESR1 protein CTD PMID:33049310 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO 17-alpha-Hydroxyprogesterone binds to and results in increased activity of ESR2 protein CTD PMID:33049310 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions ISO [17-alpha-Hydroxyprogesterone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein CTD PMID:29782964 NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
JBrowse link
G Ins2 insulin 2 multiple interactions ISO 17-alpha-Hydroxyprogesterone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; [17-alpha-Hydroxyprogesterone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein CTD PMID:29782964 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO 17-alpha-Hydroxyprogesterone binds to and results in increased activity of NR1I2 protein CTD PMID:33049310 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 multiple interactions ISO 17-alpha-Hydroxyprogesterone analog binds to and results in increased activity of NR3C1 protein CTD PMID:18060946 NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
JBrowse link
G Pgr progesterone receptor multiple interactions ISO 17-alpha-Hydroxyprogesterone analog binds to and results in increased activity of PGR protein CTD PMID:18060946 NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO 17-alpha-Hydroxyprogesterone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO TNF protein inhibits the reaction [CYP17A1 protein affects the metabolism of 17-alpha-Hydroxyprogesterone] CTD PMID:16030167 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
6beta-hydroxycortisol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 affects chemical synthesis ISO CYP3A4 protein affects the chemical synthesis of 6 beta-hydroxycortisol CTD PMID:15941677 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
cortisol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2m alpha-2-macroglobulin multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA CTD PMID:34480604 NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
increases secretion
ISO Elacridar inhibits the reaction [ABCB1 protein results in increased secretion of Hydrocortisone]; valspodar inhibits the reaction [ABCB1 protein results in increased secretion of Hydrocortisone] CTD PMID:22464980 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA CTD PMID:34480604 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions
increases expression
increases activity
ISO Hydrocortisone promotes the reaction [ABCC3 protein affects the transport of calcein AM]
Hydrocortisone results in increased expression of ABCC3 mRNA
Hydrocortisone results in increased activity of ABCC3 protein
CTD PMID:15979871 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
JBrowse link
G Acaca acetyl-CoA carboxylase alpha increases expression
multiple interactions
ISO Hydrocortisone results in increased expression of ACACA mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]
CTD PMID:30776459 PMID:33476690 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
JBrowse link
G Ackr1 atypical chemokine receptor 1 multiple interactions
increases expression
ISO Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of ACKR1 mRNA] CTD PMID:25763180 NCBI chr13:85,782,396...85,786,002
Ensembl chr13:85,782,398...85,783,983
JBrowse link
G Acly ATP citrate lyase increases expression ISO Hydrocortisone results in increased expression of ACLY mRNA CTD PMID:30776459 NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
JBrowse link
G Acsl5 acyl-CoA synthetase long-chain family member 5 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA CTD PMID:34480604 NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
JBrowse link
G Actn2 actinin alpha 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA CTD PMID:34480604 NCBI chr17:58,143,334...58,210,622
Ensembl chr17:58,142,625...58,210,622
JBrowse link
G Adam12 ADAM metallopeptidase domain 12 decreases expression ISO Hydrocortisone results in decreased expression of ADAM12 mRNA CTD PMID:21267416 NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667
JBrowse link
G Adgre5 adhesion G protein-coupled receptor E5 decreases expression ISO Hydrocortisone results in decreased expression of ADGRE5 mRNA CTD PMID:21267416 NCBI chr19:24,397,972...24,418,648
Ensembl chr19:24,398,689...24,418,638
JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 decreases expression ISO Hydrocortisone results in decreased expression of ADGRG1 mRNA CTD PMID:21267416 NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions ISO [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein] CTD PMID:33476690 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Afp alpha-fetoprotein multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA CTD PMID:34480604 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
JBrowse link
G Agt angiotensinogen decreases expression
increases secretion
ISO Hydrocortisone results in decreased expression of AGT protein
AGT protein results in increased secretion of Hydrocortisone
CTD PMID:7473517 PMID:28235592 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 increases reduction
multiple interactions
ISO AKR1D1 protein results in increased reduction of Hydrocortisone
AKR1D1 protein alternative form results in increased reduction of Hydrocortisone; AKR1D1 protein results in increased reduction of Hydrocortisone
[AKR1D1 protein alternative form results in increased reduction of Hydrocortisone] which results in increased chemical synthesis of 5-dihydrocortisol
CTD PMID:30928400 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372
JBrowse link
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation EXP Hydrocortisone results in decreased phosphorylation of AKT1 protein CTD PMID:15187100 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Akt2 AKT serine/threonine kinase 2 decreases expression ISO Hydrocortisone results in decreased expression of AKT2 mRNA CTD PMID:31075344 PMID:32535229 NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
JBrowse link
G Alb albumin multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA CTD PMID:34480604 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Aldoa aldolase, fructose-bisphosphate A multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA CTD PMID:34480604 NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
JBrowse link
G Amhr2 anti-Mullerian hormone receptor type 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA CTD PMID:34480604 NCBI chr 7:133,579,152...133,588,874
Ensembl chr 7:133,579,393...133,588,258
JBrowse link
G Anxa1 annexin A1 multiple interactions
increases expression
ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of ANXA1 mRNA] CTD PMID:25763180 PMID:34480604 NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA CTD PMID:34480604 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
JBrowse link
G Apob apolipoprotein B multiple interactions
decreases expression
ISO IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of APOB mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of APOB mRNA] CTD PMID:31075344 NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
JBrowse link
G Ar androgen receptor affects activity
affects binding
multiple interactions
ISO
EXP
Hydrocortisone affects the activity of AR protein
Hydrocortisone binds to AR protein
Hydrocortisone binds to AR protein mutant form
Hydrocortisone binds to and results in increased activity of AR protein; Hydrocortisone binds to and results in increased activity of AR protein mutant form
CTD PMID:11956172 PMID:12676605 PMID:14565775 PMID:15084347 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Arg1 arginase 1 increases expression
multiple interactions
EXP Hydrocortisone results in increased expression of ARG1 mRNA
Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]
CTD PMID:26647222 NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
JBrowse link
G Ascl1 achaete-scute family bHLH transcription factor 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA CTD PMID:34480604 NCBI chr 7:21,904,153...21,906,003
Ensembl chr 7:21,903,126...21,905,993
JBrowse link
G Bmal1 basic helix-loop-helix ARNT like 1 decreases expression ISO Hydrocortisone results in decreased expression of BMAL1 mRNA CTD PMID:21980503 NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
JBrowse link
G Bmp5 bone morphogenetic protein 5 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA CTD PMID:34480604 NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
JBrowse link
G Camk2b calcium/calmodulin-dependent protein kinase II beta multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA CTD PMID:34480604 NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
JBrowse link
G Casp3 caspase 3 increases activity
multiple interactions
ISO
EXP
Hydrocortisone results in increased activity of CASP3 protein
Hydrocortisone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]
CTD PMID:15086553 PMID:15755911 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression
multiple interactions
ISO
EXP
Hydrocortisone results in decreased expression of CCL2 protein
Hydrocortisone inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]
CTD PMID:20116850 PMID:25851902 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression ISO Hydrocortisone results in increased expression of CCL3 protein CTD PMID:20116850 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
JBrowse link
G Ccl4 C-C motif chemokine ligand 4 increases expression ISO Hydrocortisone results in increased expression of CCL4 protein CTD PMID:20116850 NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
JBrowse link
G Cd14 CD14 molecule decreases expression ISO Hydrocortisone results in decreased expression of CD14 mRNA CTD PMID:17033190 NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
JBrowse link
G Cd40 CD40 molecule decreases expression ISO Hydrocortisone results in decreased expression of CD40 protein CTD PMID:15086553 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
JBrowse link
G Cd80 Cd80 molecule decreases expression ISO Hydrocortisone results in decreased expression of CD80 protein CTD PMID:15086553 PMID:15241357 NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
JBrowse link
G Cd86 CD86 molecule decreases expression ISO Hydrocortisone results in decreased expression of CD86 protein CTD PMID:15086553 PMID:15241357 NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
JBrowse link
G Cdc20 cell division cycle 20 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA CTD PMID:34480604 NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
JBrowse link
G Cdh10 cadherin 10 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA CTD PMID:34480604 NCBI chr 2:68,628,623...68,850,995
Ensembl chr 2:68,628,780...68,850,995
JBrowse link
G Cdh5 cadherin 5 increases localization
multiple interactions
ISO Hydrocortisone results in increased localization of CDH5 protein
GGTI 298 inhibits the reaction [Hydrocortisone results in increased localization of CDH5 protein]
CTD PMID:25763180 NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
JBrowse link
G Ceacam6 CEA cell adhesion molecule 6 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA CTD PMID:34480604 NCBI chr 1:80,416,531...80,434,668
Ensembl chr 1:80,416,531...80,434,668
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions
increases expression
ISO [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of CEBPA mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; rosemarinic acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]
Hydrocortisone results in increased expression of CEBPA mRNA; Hydrocortisone results in increased expression of CEBPA protein
CTD PMID:30528684 PMID:30776459 PMID:32535229 PMID:33476690 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta affects expression
multiple interactions
ISO Hydrocortisone affects the expression of CEBPB mRNA
Mifepristone affects the reaction [Hydrocortisone affects the expression of CEBPB mRNA]
CTD PMID:30528684 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
JBrowse link
G Cidec cell death-inducing DFFA-like effector c multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA CTD PMID:34480604 NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions EXP Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein] CTD PMID:17434272 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA CTD PMID:34480604 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
JBrowse link
G Col7a1 collagen type VII alpha 1 chain decreases expression ISO Hydrocortisone results in decreased expression of COL7A1 mRNA CTD PMID:21267416 NCBI chr 8:109,604,877...109,637,252
Ensembl chr 8:109,604,861...109,637,252
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A decreases expression ISO Hydrocortisone results in decreased expression of CPT1A mRNA CTD PMID:30776459 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
JBrowse link
G Crh corticotropin releasing hormone increases abundance ISO CRH protein results in increased abundance of Hydrocortisone CTD PMID:8888355 PMID:20570051 NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
JBrowse link
G Cry1 cryptochrome circadian regulator 1 increases expression ISO Hydrocortisone results in increased expression of CRY1 mRNA CTD PMID:21980503 NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
JBrowse link
G Cryab crystallin, alpha B multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA CTD PMID:34480604 NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
JBrowse link
G Csf2 colony stimulating factor 2 decreases secretion
multiple interactions
ISO Hydrocortisone results in decreased secretion of CSF2 protein
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]
CTD PMID:10460758 PMID:15086553 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
JBrowse link
G Ctnnb1 catenin beta 1 increases localization
multiple interactions
ISO Hydrocortisone results in increased localization of CTNNB1 protein
GGTI 298 inhibits the reaction [Hydrocortisone results in increased localization of CTNNB1 protein]
CTD PMID:25763180 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 decreases expression
multiple interactions
affects expression
ISO Hydrocortisone results in decreased expression of CYP11A1 mRNA; Hydrocortisone results in decreased expression of CYP11A1 protein
HDAC1 protein affects the reaction [Hydrocortisone results in decreased expression of CYP11A1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of CYP11A1 mRNA]
Hydrocortisone affects the expression of CYP11A1 mRNA
CTD PMID:30528684 PMID:34454011 NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
JBrowse link
G Cyp11b2 cytochrome P450, family 11, subfamily b, polypeptide 2 increases chemical synthesis
multiple interactions
affects metabolic processing
ISO CYP11B1 protein results in increased chemical synthesis of Hydrocortisone
3',4'-dimethoxyflavone promotes the reaction [CYP11B1 protein results in increased chemical synthesis of Hydrocortisone]; alpha-naphthoflavone promotes the reaction [CYP11B1 protein results in increased chemical synthesis of Hydrocortisone]; beta-Naphthoflavone promotes the reaction [CYP11B1 protein results in increased chemical synthesis of Hydrocortisone]
CYP11B1 protein affects the metabolism of Hydrocortisone
CTD PMID:16030167 PMID:16054388 PMID:19900470 PMID:22172629 NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions EXP [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein] CTD PMID:8674863 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions
decreases expression
EXP [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]
Hydrocortisone results in decreased expression of CYP1B1 protein
CTD PMID:8674863 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA CTD PMID:34480604 NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
JBrowse link
G Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA CTD PMID:34480604 NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 increases expression EXP Hydrocortisone results in increased expression of CYP2B1 mRNA; Hydrocortisone results in increased expression of CYP2B1 protein CTD PMID:10476907 NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 increases expression EXP Hydrocortisone results in increased expression of CYP2E1 mRNA; Hydrocortisone results in increased expression of CYP2E1 protein CTD PMID:10476907 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Cyp2s1 cytochrome P450, family 2, subfamily s, polypeptide 1 decreases expression ISO Hydrocortisone results in decreased expression of CYP2S1 mRNA CTD PMID:22155357 NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases expression
affects metabolic processing
multiple interactions
affects hydroxylation
increases metabolic processing
EXP
ISO
Hydrocortisone results in increased expression of CYP3A2 mRNA
CYP3A4 protein affects the metabolism of Hydrocortisone
CYP3A4 promoter mutant form inhibits the reaction [Hydrocortisone results in increased expression of CYP3A4 mRNA]; kaempferol inhibits the reaction [CYP3A4 protein results in increased degradation of Hydrocortisone]; Quercetin inhibits the reaction [CYP3A4 protein results in increased degradation of Hydrocortisone]
CYP3A4 protein affects the hydroxylation of Hydrocortisone
CYP3A4 protein results in increased metabolism of Hydrocortisone
CTD PMID:2271712 PMID:10476907 PMID:11907490 PMID:12505310 PMID:15025748 More... NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 increases expression EXP Hydrocortisone results in increased expression of CYP3A23-3A1 mRNA; Hydrocortisone results in increased expression of CYP3A23-3A1 protein CTD PMID:10476907 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 increases expression
multiple interactions
ISO Hydrocortisone results in increased expression of CYP3A5 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA
CTD PMID:23223499 PMID:34480604 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
JBrowse link
G Cyp4a1 cytochrome P450, family 4, subfamily a, polypeptide 1 increases expression EXP Hydrocortisone results in increased expression of CYP4A1 mRNA CTD PMID:10476907 NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
JBrowse link
G Dcc DCC netrin 1 receptor multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA CTD PMID:34480604 NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740
JBrowse link
G Dcn decorin multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA CTD PMID:34480604 NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
JBrowse link
G Dcx doublecortin multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA CTD PMID:34480604 NCBI chr  X:107,430,767...107,573,612
Ensembl chr  X:107,430,767...107,507,476
JBrowse link
G Dhrs9 dehydrogenase/reductase 9 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA CTD PMID:34480604 NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA CTD PMID:34480604 NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458
JBrowse link
G Dsg1 desmoglein 1 multiple interactions ISO Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; Hydrocortisone inhibits the reaction [[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of DSG1 mRNA] CTD PMID:32076005 NCBI chr18:11,674,687...11,705,383
Ensembl chr18:11,674,402...11,703,443
JBrowse link
G Dusp1 dual specificity phosphatase 1 increases expression ISO Hydrocortisone results in increased expression of DUSP1 mRNA CTD PMID:21980503 NCBI chr10:16,680,489...16,683,276 JBrowse link
G Ebf1 EBF transcription factor 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA CTD PMID:34480604 NCBI chr10:29,095,858...29,489,142
Ensembl chr10:29,099,933...29,487,665
JBrowse link
G Ebf3 EBF transcription factor 3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA CTD PMID:34480604 NCBI chr 1:191,996,726...192,114,713
Ensembl chr 1:191,996,730...192,114,359
JBrowse link
G Ecscr endothelial cell surface expressed chemotaxis and apoptosis regulator multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA CTD PMID:34480604 NCBI chr18:27,309,711...27,319,106
Ensembl chr18:27,309,718...27,319,032
JBrowse link
G Egf epidermal growth factor multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ESRG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of H2BC14 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGHV3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KRT6A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA; Gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]; Hydrocortisone inhibits the reaction [EGF protein results in increased expression of PTGS2 mRNA]; Indomethacin promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]] CTD PMID:17805209 PMID:34480604 NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
G Egln3 egl-9 family hypoxia-inducible factor 3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA CTD PMID:34480604 NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
JBrowse link
G Elavl3 ELAV like RNA binding protein 3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA CTD PMID:34480604 NCBI chr 8:20,547,108...20,583,369
Ensembl chr 8:20,550,201...20,583,641
JBrowse link
G Elavl4 ELAV like RNA binding protein 4 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA CTD PMID:34480604 NCBI chr 5:125,056,848...125,200,543
Ensembl chr 5:125,056,848...125,200,446
JBrowse link
G Emx2 empty spiracles homeobox 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA CTD PMID:34480604 NCBI chr 1:258,626,584...258,633,594
Ensembl chr 1:258,626,584...258,633,594
JBrowse link
G Epo erythropoietin increases expression ISO Hydrocortisone results in increased expression of EPO protein CTD PMID:10694834 NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
JBrowse link
G Errfi1 ERBB receptor feedback inhibitor 1 increases expression EXP Hydrocortisone results in increased expression of ERRFI1 mRNA CTD PMID:1472065 NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO Hydrocortisone binds to and results in increased activity of ESR1 protein CTD PMID:12676605 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Fabp1 fatty acid binding protein 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA CTD PMID:34480604 NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions ISO [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA] CTD PMID:33476690 NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
JBrowse link
G Fah fumarylacetoacetate hydrolase multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA CTD PMID:34480604 NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505
JBrowse link
G Fas Fas cell surface death receptor multiple interactions
increases expression
ISO [HIV Envelope Protein gp120 co-treated with Hydrocortisone] results in increased expression of FAS mRNA; Hydrocortisone promotes the reaction [Mitoxantrone results in increased expression of FAS]
Hydrocortisone results in increased expression of FAS protein
CTD PMID:9676859 PMID:11075952 PMID:15086553 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
JBrowse link
G Fasn fatty acid synthase multiple interactions
increases expression
ISO [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Resveratrol inhibits the reaction [Hydrocortisone results in increased expression of FASN mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA] CTD PMID:30776459 PMID:33476690 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
JBrowse link
G Fbxo32 F-box protein 32 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA CTD PMID:34480604 NCBI chr 7:89,731,626...89,764,761
Ensembl chr 7:89,730,232...89,765,436
JBrowse link
G Fgb fibrinogen beta chain multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA CTD PMID:34480604 NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
JBrowse link
G Fgf7 fibroblast growth factor 7 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA CTD PMID:34480604 NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
JBrowse link
G Fgf9 fibroblast growth factor 9 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ESRG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of H2BC14 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGHV3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KRT6A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA CTD PMID:34480604 NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 increases expression ISO Hydrocortisone results in increased expression of FKBP5 mRNA CTD PMID:21267416 NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
JBrowse link
G Flg filaggrin decreases expression
multiple interactions
ISO Hydrocortisone results in decreased expression of FLG mRNA
Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]
CTD PMID:32076005 NCBI chr 2:178,888,688...178,912,731 JBrowse link
G Flrt3 fibronectin leucine rich transmembrane protein 3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA CTD PMID:34480604 NCBI chr 3:127,994,491...128,008,137
Ensembl chr 3:127,994,226...128,007,841
JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA CTD PMID:34480604 NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
JBrowse link
G Foxd3 forkhead box D3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA CTD PMID:34480604 NCBI chr 5:114,334,693...114,337,788
Ensembl chr 5:114,335,408...114,336,817
JBrowse link
G Foxg1 forkhead box G1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA CTD PMID:34480604 NCBI chr 6:66,674,797...66,677,611
Ensembl chr 6:66,666,587...66,678,607
JBrowse link
G Foxo1 forkhead box O1 increases expression ISO Hydrocortisone results in increased expression of FOXO1 mRNA CTD PMID:21267416 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA CTD PMID:34480604 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
JBrowse link
G Gata6 GATA binding protein 6 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA CTD PMID:34480604 NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression
multiple interactions
EXP
ISO
Hydrocortisone results in increased expression of GCLC mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA
CTD PMID:10978506 PMID:34480604 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA CTD PMID:34480604 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
JBrowse link
G Gh1 growth hormone 1 increases expression ISO Hydrocortisone results in increased expression of GH1 protein CTD PMID:15833589 NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
JBrowse link
G Gnpat glyceronephosphate O-acyltransferase multiple interactions
increases expression
ISO Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of GNPAT mRNA] CTD PMID:25763180 NCBI chr19:52,822,326...52,848,872
Ensembl chr19:52,822,319...52,852,361
JBrowse link
G Gpr183 G protein-coupled receptor 183 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA CTD PMID:34480604 NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559
JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA CTD PMID:34480604 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA CTD PMID:34480604 NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
JBrowse link
G Gria3 glutamate ionotropic receptor AMPA type subunit 3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA CTD PMID:34480604 NCBI chr  X:120,238,515...120,504,106
Ensembl chr  X:120,238,534...120,504,096
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 increases expression
multiple interactions
ISO Hydrocortisone results in increased expression of GSTA1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; Hydrocortisone results in increased expression of and results in increased activity of GSTA1 protein
CTD PMID:11297599 PMID:34480604 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
JBrowse link
G Gsta2 glutathione S-transferase alpha 2 multiple interactions
decreases expression
increases expression
EXP
ISO
Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of GSTA2 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA
Hydrocortisone results in decreased expression of GSTA2 mRNA
Hydrocortisone results in increased expression of GSTA2 mRNA
CTD PMID:10476907 PMID:11502894 PMID:22606287 PMID:34480604 NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
JBrowse link
G Gsto1 glutathione S-transferase omega 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA CTD PMID:34480604 NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA CTD PMID:34480604 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
G Gucy1a1 guanylate cyclase 1 soluble subunit alpha 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A3 mRNA CTD PMID:34480604 NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
JBrowse link
G H6pd hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) increases expression ISO Hydrocortisone results in increased expression of H6PD mRNA CTD PMID:20410225 NCBI chr 5:160,434,499...160,470,203
Ensembl chr 5:160,438,697...160,470,171
JBrowse link
G Hand2 heart and neural crest derivatives expressed 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA CTD PMID:34480604 NCBI chr16:32,917,826...32,919,880
Ensembl chr16:32,917,823...32,919,891
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA CTD PMID:34480604 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
JBrowse link
G Hdac1 histone deacetylase 1 multiple interactions
increases expression
ISO HDAC1 protein affects the reaction [Hydrocortisone results in decreased expression of CYP11A1 mRNA]; SF1 protein inhibits the reaction [Hydrocortisone results in increased expression of HDAC1 mRNA] CTD PMID:34454011 NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
JBrowse link
G Hes5 hes family bHLH transcription factor 5 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA CTD PMID:34480604 NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001
JBrowse link
G Hgf hepatocyte growth factor decreases expression ISO Hydrocortisone results in decreased expression of HGF protein CTD PMID:1459995 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions
decreases expression
ISO IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of HMGCR mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of HMGCR mRNA] CTD PMID:31075344 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA CTD PMID:34480604 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hoxa1 homeobox A1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA CTD PMID:34480604 NCBI chr 4:81,255,814...81,258,504
Ensembl chr 4:81,255,883...81,258,504
JBrowse link
G Hoxa2 homeobox A2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA CTD PMID:34480604 Ensembl chr 4:81,262,768...81,265,044 JBrowse link
G Hoxa5 homeo box A5 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA CTD PMID:34480604 NCBI chr 4:81,302,341...81,306,234
Ensembl chr 4:81,302,353...81,306,234
JBrowse link
G Hoxb3 homeo box B3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA CTD PMID:34480604 NCBI chr10:81,258,739...81,314,134
Ensembl chr10:81,299,357...81,313,107
JBrowse link
G Hoxd4 homeo box D4 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA CTD PMID:34480604 NCBI chr 3:59,614,464...59,634,042
Ensembl chr 3:59,614,464...59,631,528
JBrowse link
G Hoxd8 homeobox D8 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA CTD PMID:34480604 NCBI chr 3:59,607,864...59,610,358
Ensembl chr 3:59,607,996...59,610,361
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions
affects expression
increases oxidation
affects response to substance
increases chemical synthesis
increases expression
increases activity
affects oxidation
ISO
EXP
[HSD11B1 protein results in increased metabolism of Ketosteroids] which results in increased chemical synthesis of Hydrocortisone; [HSD11B1 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone; [HSD11B1 protein results in increased reduction of Cortisone] which results in increased chemical synthesis of Hydrocortisone; Dinoprostone promotes the reaction [HSD11B1 protein affects the oxidation of Hydrocortisone]; Hydrocortisone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA]; Mifepristone affects the reaction [Hydrocortisone affects the expression of HSD11B1 mRNA]; perfluorooctane sulfonic acid inhibits the reaction [Hydrocortisone results in increased expression of HSD11B1]
[HSD11B1 protein affects the susceptibility to Hydrocortisone] which results in decreased activity of NFE2L2 protein
HSD11B1 protein results in increased chemical synthesis of Hydrocortisone
Hydrocortisone results in increased expression of HSD11B1; Hydrocortisone results in increased expression of HSD11B1 mRNA; Hydrocortisone results in increased expression of HSD11B1 protein
Hydrocortisone results in increased activity of HSD11B1 protein
CTD PMID:16054388 PMID:16751407 PMID:17761898 PMID:20410225 PMID:22178014 More... NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 affects binding
decreases expression
increases oxidation
multiple interactions
increases metabolic processing
ISO HSD11B2 protein binds to Hydrocortisone
Hydrocortisone results in decreased expression of HSD11B2 mRNA; Hydrocortisone results in decreased expression of HSD11B2 protein
HSD11B2 protein results in increased oxidation of Hydrocortisone
[HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of HSD11B2 mRNA]; Ziram inhibits the reaction [[HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone]; Ziram inhibits the reaction [HSD11B2 protein results in increased oxidation of Hydrocortisone]
HSD11B2 protein results in increased metabolism of Hydrocortisone
CTD PMID:22273746 PMID:22796344 PMID:26859423 PMID:30528684 NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 affects binding ISO Hydrocortisone binds to HSD3B1 protein CTD PMID:25526675 NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
JBrowse link
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 multiple interactions ISO [galaxolide results in decreased expression of [HSD3B2 co-treated with CYP21A2]] which results in decreased chemical synthesis of Hydrocortisone CTD PMID:23084589 NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
decreases expression
ISO Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]]
Hydrocortisone results in decreased expression of ICAM1 protein
CTD PMID:9150321 PMID:15086553 PMID:15358673 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Ifi44 interferon-induced protein 44 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA CTD PMID:34480604 NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844
JBrowse link
G Ifnb1 interferon beta 1 multiple interactions
decreases secretion
ISO IFNB1 protein inhibits the reaction [IGF2 protein results in increased secretion of Hydrocortisone]; Mitotane promotes the reaction [IFNB1 protein results in decreased secretion of Hydrocortisone] CTD PMID:23507702 NCBI chr 5:103,020,969...103,021,523
Ensembl chr 5:103,020,969...103,021,523
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; Hydrocortisone inhibits the reaction [nickel sulfate results in increased secretion of IFNG protein] CTD PMID:15663561 PMID:29594315 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions
decreases expression
ISO IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of APOB mRNA]; IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of HMGCR mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of IGF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 protein]
Hydrocortisone results in decreased expression of IGF1 mRNA; Hydrocortisone results in decreased expression of IGF1 protein
CTD PMID:30528684 PMID:31075344 PMID:32535229 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
JBrowse link
G Igf1r insulin-like growth factor 1 receptor affects expression
multiple interactions
ISO Hydrocortisone affects the expression of IGF1R mRNA
Mifepristone affects the reaction [Hydrocortisone affects the expression of IGF1R mRNA]
CTD PMID:30528684 NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
JBrowse link
G Igf2 insulin-like growth factor 2 multiple interactions
increases secretion
ISO IFNB1 protein inhibits the reaction [IGF2 protein results in increased secretion of Hydrocortisone] CTD PMID:23507702 NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO Hydrocortisone promotes the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]] CTD PMID:23275455 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 decreases expression ISO Hydrocortisone results in decreased expression of IGFBP5 mRNA CTD PMID:21267416 NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
JBrowse link
G Igfbp7 insulin-like growth factor binding protein 7 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA CTD PMID:34480604 NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314
JBrowse link
G Il10 interleukin 10 multiple interactions ISO [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA] CTD PMID:29777833 PMID:33476690 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il17a interleukin 17A multiple interactions ISO [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA] CTD PMID:33476690 NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
JBrowse link
G Il1a interleukin 1 alpha decreases expression
multiple interactions
ISO Hydrocortisone results in decreased expression of IL1A mRNA
Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]; Hydrocortisone inhibits the reaction [IL1A protein results in increased expression of MMP9 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]; NR3C1 protein promotes the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]
CTD PMID:18722610 PMID:21980503 NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
JBrowse link
G Il1b interleukin 1 beta increases abundance
decreases expression
multiple interactions
ISO
EXP
IL1B protein results in increased abundance of Hydrocortisone
Hydrocortisone results in decreased expression of IL1B mRNA
Hydrocortisone inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]
CTD PMID:10460758 PMID:12548226 PMID:25851902 PMID:29594315 PMID:33476690 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA CTD PMID:34480604 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein] CTD PMID:29594315 PMID:29777833 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il2ra interleukin 2 receptor subunit alpha decreases expression ISO Hydrocortisone results in decreased expression of IL2RA protein CTD PMID:15086553 NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
JBrowse link
G Il4 interleukin 4 decreases expression ISO Hydrocortisone results in decreased expression of IL4 protein CTD PMID:7988651 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
JBrowse link
G Il5 interleukin 5 multiple interactions
decreases expression
ISO Hydrocortisone inhibits the reaction [nickel sulfate results in increased secretion of IL5 protein]
Hydrocortisone results in decreased expression of IL5 protein
CTD PMID:7988651 PMID:15663561 NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
JBrowse link
G Il6 interleukin 6 decreases secretion
decreases expression
ISO Hydrocortisone results in decreased secretion of IL6 protein
Hydrocortisone results in decreased expression of IL6 protein
CTD PMID:12682474 PMID:16255036 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Ins2 insulin 2 multiple interactions
increases expression
ISO [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Octreotide inhibits the reaction [Hydrocortisone results in increased expression of INS protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; rosemarinic acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; rosemarinic acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] CTD PMID:7473517 PMID:7792821 PMID:7917157 PMID:33476690 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
G Isl1 ISL LIM homeobox 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA CTD PMID:34480604 NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584
JBrowse link
G Itga10 integrin subunit alpha 10 increases expression ISO Hydrocortisone results in increased expression of ITGA10 mRNA CTD PMID:21267416 NCBI chr 2:184,182,869...184,202,172
Ensembl chr 2:184,182,869...184,202,172
JBrowse link
G Itga5 integrin subunit alpha 5 increases expression ISO Hydrocortisone results in increased expression of ITGA5 mRNA CTD PMID:21267416 NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837
JBrowse link
G Ivl involucrin decreases expression ISO Hydrocortisone results in decreased expression of IVL mRNA CTD PMID:32076005 NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA CTD PMID:34480604 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
JBrowse link
G Klk1 kallikrein 1 increases export ISO Hydrocortisone results in increased export of KLK1 protein CTD PMID:7473517 NCBI chr 1:94,642,722...94,646,714
Ensembl chr 1:94,642,687...94,646,754
JBrowse link
G Krt1 keratin 1 multiple interactions ISO Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; Hydrocortisone inhibits the reaction [[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of KRT1 mRNA] CTD PMID:32076005 NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
JBrowse link
G Krt10 keratin 10 multiple interactions ISO Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; Hydrocortisone inhibits the reaction [[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of KRT10 mRNA] CTD PMID:32076005 NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701
JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA CTD PMID:34480604 NCBI chr 5:141,888,319...141,916,992
Ensembl chr 5:141,888,326...141,903,794
JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions
decreases expression
ISO Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of LDLR mRNA] CTD PMID:31075344 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
JBrowse link
G Lef1 lymphoid enhancer binding factor 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA CTD PMID:34480604 NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
JBrowse link
G Loricrin loricrin cornified envelope precursor protein decreases expression ISO Hydrocortisone results in decreased expression of LORICRIN mRNA CTD PMID:32076005 NCBI chr 2:177,558,062...177,559,980
Ensembl chr 2:177,558,252...177,559,807
JBrowse link
G Lpl lipoprotein lipase multiple interactions ISO Hydrocortisone results in decreased activity of and results in decreased expression of LPL protein CTD PMID:17549480 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
JBrowse link
G Lum lumican multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA CTD PMID:34480604 NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793
JBrowse link
G Ly75 lymphocyte antigen 75 decreases expression ISO Hydrocortisone results in decreased expression of LY75 protein CTD PMID:15086553 NCBI chr 3:44,764,702...44,852,219
Ensembl chr 3:44,765,122...44,852,374
JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA CTD PMID:34480604 NCBI chr10:105,903,307...105,911,845
Ensembl chr10:105,903,237...105,912,026
JBrowse link
G Maoa monoamine oxidase A increases expression ISO Hydrocortisone results in increased expression of MAOA mRNA CTD PMID:21267416 NCBI chr  X:6,032,172...6,098,308
Ensembl chr  X:6,030,795...6,099,593
JBrowse link
G Map3k7 mitogen activated protein kinase kinase kinase 7 decreases expression ISO Hydrocortisone results in decreased expression of MAP3K7 mRNA CTD PMID:21267416 NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597
JBrowse link
G Mlip muscular LMNA-interacting protein multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA CTD PMID:34480604 NCBI chr 8:77,935,087...78,204,725
Ensembl chr 8:77,935,079...78,204,254
JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA CTD PMID:34480604 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]; Hydrocortisone inhibits the reaction [IL1A protein results in increased expression of MMP9 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]; NR3C1 protein promotes the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]] CTD PMID:18722610 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Mpzl1 myelin protein zero-like 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA CTD PMID:34480604 NCBI chr13:77,852,467...77,889,305
Ensembl chr13:77,852,467...77,896,616
JBrowse link
G Mt1 metallothionein 1 increases expression EXP Hydrocortisone results in increased expression of MT1A mRNA CTD PMID:6687866 NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
JBrowse link
G Myl4 myosin, light chain 4 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA CTD PMID:34480604 NCBI chr10:89,449,456...89,485,365
Ensembl chr10:89,449,443...89,485,363
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO
EXP
[Hydrocortisone results in increased activity of NR3C1 protein] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA
[HSD11B1 protein affects the susceptibility to Hydrocortisone] which results in decreased activity of NFE2L2 protein; Hydrocortisone inhibits the reaction [Hydrogen Peroxide promotes the reaction [sulforaphane results in increased expression of NFE2L2 protein]]; Hydrocortisone inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of NFE2L2 protein]
CTD PMID:22606287 PMID:33476690 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
increases expression
ISO [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of NFKBIA mRNA] CTD PMID:25763180 PMID:33476690 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of NOS2 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of NOS2 protein] CTD PMID:17434272 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nppa natriuretic peptide A increases expression
decreases secretion
ISO Hydrocortisone results in increased expression of NPPA protein
NPPA protein results in decreased secretion of Hydrocortisone
CTD PMID:2434734 PMID:2931268 PMID:7473517 NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
JBrowse link
G Npy neuropeptide Y affects expression ISO Hydrocortisone affects the expression of NPY protein CTD PMID:7955553 NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP
ISO
Hydrocortisone inhibits the reaction [Hydrogen Peroxide promotes the reaction [sulforaphane results in increased expression of NQO1 protein]]; Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of NQO1 mRNA]; Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of NQO1 protein]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA
CTD PMID:22606287 PMID:34480604 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Nr2f1 nuclear receptor subfamily 2, group F, member 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA CTD PMID:34480604 NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123
JBrowse link
G Nr2f2 nuclear receptor subfamily 2, group F, member 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA CTD PMID:34480604 NCBI chr 1:124,008,282...124,022,521
Ensembl chr 1:124,009,181...124,022,031
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 multiple interactions
affects localization
increases activity
affects binding
increases phosphorylation
decreases expression
affects abundance
increases expression
ISO
EXP
1,1-bis(4-hydroxyphenyl)cyclohexane inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; 1,1-bis(4-hydroxyphenyl)cyclohexane inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; 2,2',4,4',5-brominated diphenyl ether inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; 3-phenoxybenzoic acid inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; [Hydrocortisone co-treated with Progesterone] results in increased expression of NR3C1 mRNA; [Hydrocortisone results in increased activity of NR3C1 protein] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; Atrazine inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bifenthrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol A analog inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol A inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; bisphenol A inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol B inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; bisphenol B inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; croneton inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; cyhalothrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; cypermethrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; DDT inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Hydrocortisone binds to and affects the activity of NR3C1 protein; Hydrocortisone binds to and results in increased activity of NR3C1 protein; Hydrocortisone results in increased expression of and affects the localization of NR3C1 protein; Methoxychlor inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Mifepristone inhibits the reaction [Hydrocortisone affects the localization of NR3C1 protein]; Mifepristone inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 protein]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of SIRT1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; NR3C1 protein alternative form inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein alternative form]; NR3C1 protein promotes the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Pesticides inhibits the reaction [Hydrocortisone results in increased expression of NR3C1 mRNA]; Polybrominated Biphenyls metabolite inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; resmethrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Soil Pollutants inhibits the reaction [Hydrocortisone results in increased expression of NR3C1 mRNA]; Thiram inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; tributyl phosphate inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; triphenyl phosphate inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; triphenyl phosphate metabolite inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; tris(1,3-dichloro-2-propyl)phosphate inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]
NR3C1 protein binds to Hydrocortisone
Hydrocortisone promotes the reaction [[NR3C1 protein binds to TAT promoter] which results in increased expression of TAT mRNA]
Hydrocortisone results in increased phosphorylation of NR3C1 protein
Hydrocortisone results in decreased expression of NR3C1 mRNA; Hydrocortisone results in decreased expression of NR3C1 protein
Fluoxetine promotes the reaction [Hydrocortisone results in increased activity of NR3C1 protein]
Hydrocortisone analog binds to NR3C1 protein
NR3C1 gene polymorphism affects the abundance of Hydrocortisone
Hydrocortisone results in increased expression of NR3C1; Hydrocortisone results in increased expression of NR3C1 mRNA
CTD PMID:926113 PMID:1597467 PMID:11956172 PMID:12871829 PMID:15362971 More... NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
JBrowse link
G Nr3c2 nuclear receptor subfamily 3, group C, member 2 multiple interactions
increases activity
ISO [Fludrocortisone binds to and results in increased activity of NR3C2 protein] which results in decreased abundance of Hydrocortisone
Hydrocortisone results in increased activity of NR3C2 protein
CTD PMID:15362971 PMID:15780662 PMID:16566900 NCBI chr19:30,715,648...31,059,885
Ensembl chr19:30,715,648...31,059,885
JBrowse link
G Nr6a1 nuclear receptor subfamily 6, group A, member 1 decreases expression ISO Hydrocortisone results in decreased expression of NR6A1 mRNA CTD PMID:21267416 NCBI chr 3:22,495,109...22,683,132
Ensembl chr 3:22,496,943...22,683,131
JBrowse link
G Ocln occludin increases expression ISO Hydrocortisone results in increased expression of OCLN mRNA CTD PMID:25763180 NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
JBrowse link
G Oxt oxytocin/neurophysin I prepropeptide affects abundance ISO OXT protein affects the abundance of Hydrocortisone CTD PMID:16554389 NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490
JBrowse link
G Paep progestagen associated endometrial protein increases metabolic processing ISO PAEP protein modified form results in increased metabolism of Hydrocortisone CTD PMID:17649829 NCBI chr 3:8,531,136...8,534,430
Ensembl chr 3:8,531,138...8,534,430
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 multiple interactions
increases expression
EXP 3-phenoxybenzoic acid inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; bifenthrin inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; DDT inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA] CTD PMID:26647222 NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
JBrowse link
G Pcna proliferating cell nuclear antigen decreases expression ISO Hydrocortisone results in decreased expression of PCNA protein CTD PMID:17549480 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Pde1a phosphodiesterase 1A multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA CTD PMID:34480604 NCBI chr 3:64,745,140...65,025,178
Ensembl chr 3:64,747,269...65,024,874
JBrowse link
G Per1 period circadian regulator 1 increases expression ISO Hydrocortisone results in increased expression of PER1 mRNA CTD PMID:21980503 NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431
JBrowse link
G Pln phospholamban multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA CTD PMID:34480604 NCBI chr20:32,629,537...32,639,559 JBrowse link
G Pnpla2 patatin-like phospholipase domain containing 2 decreases expression ISO Hydrocortisone results in decreased expression of PNPLA2 mRNA CTD PMID:30776459 NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
JBrowse link
G Pomc proopiomelanocortin increases response to substance
multiple interactions
increases abundance
increases secretion
ISO POMC protein results in increased susceptibility to Hydrocortisone
Lead inhibits the reaction [POMC protein modified form results in increased secretion of Hydrocortisone]; Melatonin inhibits the reaction [POMC protein results in increased abundance of Hydrocortisone]
POMC protein results in increased secretion of Hydrocortisone
CTD PMID:1321309 PMID:3015460 PMID:9881897 PMID:11082157 PMID:21332028 More... NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
JBrowse link
G Pou5f1 POU class 5 homeobox 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA CTD PMID:34480604 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA] CTD PMID:33476690 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Ppard peroxisome proliferator-activated receptor delta multiple interactions ISO [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA] CTD PMID:33476690 NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein] CTD PMID:33476690 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions ISO [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; rosemarinic acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA] CTD PMID:33476690 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Prl prolactin multiple interactions EXP [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] affects the metabolism of 9,10-Dimethyl-1,2-benzanthracene; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein] CTD PMID:8674863 NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
JBrowse link
G Prune2 prune homolog 2 with BCH domain decreases expression ISO Hydrocortisone results in decreased expression of PRUNE2 mRNA CTD PMID:21267416 NCBI chr 1:214,352,586...214,624,848
Ensembl chr 1:214,352,955...214,622,650
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression
ISO
EXP
Hydrocortisone inhibits the reaction [EGF protein results in increased expression of PTGS2 mRNA]
Hydrocortisone results in increased expression of PTGS2 protein
Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of PTGS2 protein]
CTD PMID:17805209 PMID:18650268 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Rap1a RAP1A, member of RAS oncogene family increases expression
multiple interactions
ISO Hydrocortisone results in increased expression of RAP1A mRNA
Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of RAP1A mRNA]
CTD PMID:25763180 NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
JBrowse link
G Rapgef3 Rap guanine nucleotide exchange factor 3 multiple interactions
increases expression
ISO Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of RAPGEF3 mRNA] CTD PMID:25763180 NCBI chr 7:128,875,772...128,898,203
Ensembl chr 7:128,875,773...128,898,521
JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA CTD PMID:34480604 NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
JBrowse link
G Rbbp7 RB binding protein 7, chromatin remodeling factor affects response to substance ISO RBBP7 protein affects the susceptibility to Hydrocortisone CTD PMID:12767060 NCBI chr  X:31,913,080...31,931,245
Ensembl chr  X:31,913,081...31,931,226
JBrowse link
G Rbm20 RNA binding motif protein 20 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA CTD PMID:34480604 NCBI chr 1:252,683,760...252,907,465
Ensembl chr 1:252,683,771...252,886,060
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]] CTD PMID:15358673 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Ren renin decreases expression ISO Hydrocortisone results in decreased expression of REN protein CTD PMID:7473517 PMID:15743397 NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
JBrowse link
G Rora RAR-related orphan receptor A increases expression ISO Hydrocortisone results in increased expression of RORA mRNA CTD PMID:21980503 NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931
JBrowse link
G Rrad RRAD, Ras related glycolysis inhibitor and calcium channel regulator multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA CTD PMID:34480604 NCBI chr19:354,184...357,424
Ensembl chr19:354,198...357,417
JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions
decreases expression
ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of SCARB1 mRNA] CTD PMID:31075344 PMID:34480604 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
JBrowse link
G Scnn1a sodium channel epithelial 1 subunit alpha increases expression ISO Hydrocortisone results in increased expression of SCNN1A mRNA CTD PMID:17715387 NCBI chr 4:158,122,962...158,146,184
Ensembl chr 4:158,122,962...158,146,181
JBrowse link
G Scnn1b sodium channel epithelial 1 subunit beta increases expression ISO Hydrocortisone results in increased expression of SCNN1B mRNA CTD PMID:17715387 NCBI chr 1:176,430,063...176,484,451
Ensembl chr 1:176,430,103...176,484,451
JBrowse link
G Scnn1g sodium channel epithelial 1 subunit gamma increases expression ISO Hydrocortisone results in increased expression of SCNN1G mRNA CTD PMID:17715387 NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816
JBrowse link
G Sema3c semaphorin 3C multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA CTD PMID:34480604 NCBI chr 4:17,583,212...17,747,234
Ensembl chr 4:17,583,212...17,746,534
JBrowse link
G Serpina1 serpin family A member 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA CTD PMID:34480604 NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339
JBrowse link
G Serpinb1a serpin family B member 1A multiple interactions EXP
ISO
Hydrocortisone results in increased cleavage of and results in increased activity of and affects the localization of SERPINB1A protein modified form
Hydrocortisone results in increased cleavage of and results in increased activity of and affects the localization of SERPINB1 protein modified form
CTD PMID:25447644 NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102
JBrowse link
G Serpinc1 serpin family C member 1 increases expression ISO Hydrocortisone results in increased expression of SERPINC1 protein CTD PMID:12682474 NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293
JBrowse link
G Sf1 splicing factor 1 multiple interactions
decreases expression
ISO Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of SF1 mRNA]; SF1 protein inhibits the reaction [Hydrocortisone results in increased expression of HDAC1 mRNA] CTD PMID:34454011 NCBI chr 1:203,670,016...203,683,432
Ensembl chr 1:203,670,018...203,684,330
JBrowse link
G Sfrp2 secreted frizzled-related protein 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA CTD PMID:34480604 NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
JBrowse link
G Sftpb surfactant protein B increases expression ISO Hydrocortisone results in increased expression of SFTPB mRNA CTD PMID:2539393 NCBI chr 4:104,359,303...104,368,439
Ensembl chr 4:104,359,396...104,368,436
JBrowse link
G Sftpc surfactant protein C increases expression ISO Hydrocortisone results in increased expression of SFTPC mRNA CTD PMID:2539393 NCBI chr15:45,596,565...45,599,615
Ensembl chr15:45,596,574...45,610,777
JBrowse link
G Sh3bp5 SH3-domain binding protein 5 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA CTD PMID:34480604 NCBI chr16:6,583,462...6,678,344
Ensembl chr16:6,583,465...6,698,975
JBrowse link
G Sirt1 sirtuin 1 decreases expression
multiple interactions
ISO Hydrocortisone results in decreased expression of SIRT1 mRNA
NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of SIRT1 mRNA]
CTD PMID:30776459 NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO Hydrocortisone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
G Slc23a2 solute carrier family 23 member 2 multiple interactions ISO Hydrocortisone inhibits the reaction [SLC23A2 protein results in increased uptake of Ascorbic Acid] CTD PMID:17092984 NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343
JBrowse link
G Slc5a5 solute carrier family 5 member 5 multiple interactions ISO 1-Methyl-3-isobutylxanthine promotes the reaction [[Tretinoin co-treated with Hydrocortisone] affects the localization of SLC5A5 protein]; 1-Methyl-3-isobutylxanthine promotes the reaction [[Tretinoin co-treated with Hydrocortisone] results in increased expression of SLC5A5 protein]; Colforsin inhibits the reaction [[Tretinoin co-treated with Hydrocortisone] results in increased activity of SLC5A5 protein]; Hydrocortisone promotes the reaction [Tretinoin affects the localization of SLC5A5 protein]; Hydrocortisone promotes the reaction [Tretinoin results in increased expression of SLC5A5 protein] CTD PMID:16439463 NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
JBrowse link
G Sox1 SRY-box transcription factor 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA CTD PMID:34480604 NCBI chr16:77,134,795...77,139,628
Ensembl chr16:77,137,584...77,138,762
JBrowse link
G Sox2 SRY-box transcription factor 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA CTD PMID:34480604 NCBI chr 2:117,536,929...117,539,338
Ensembl chr 2:117,536,929...117,539,338
JBrowse link
G Sptssb serine palmitoyltransferase, small subunit B multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA CTD PMID:34480604 NCBI chr 2:154,133,728...154,162,127
Ensembl chr 2:154,133,733...154,163,120
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA CTD PMID:34480604 NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 increases expression
multiple interactions
ISO Hydrocortisone results in increased expression of SREBF1 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; Resveratrol inhibits the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]
CTD PMID:30776459 PMID:33476690 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Srxn1 sulfiredoxin 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA CTD PMID:34480604 NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
JBrowse link
G Star steroidogenic acute regulatory protein decreases expression
multiple interactions
ISO Hydrocortisone results in decreased expression of STAR mRNA; Hydrocortisone results in decreased expression of STAR protein
Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of STAR mRNA]
CTD PMID:30528684 NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
JBrowse link
G Stmn2 stathmin 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA CTD PMID:34480604 NCBI chr 2:93,204,690...93,252,011
Ensembl chr 2:93,204,692...93,252,011
JBrowse link
G Tat tyrosine aminotransferase multiple interactions
increases expression
increases activity
ISO
EXP
Diethylnitrosamine inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]; o-Aminoazotoluene inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]
Hydrocortisone results in increased expression of TAT mRNA
beryllium sulfate inhibits the reaction [Hydrocortisone results in increased expression of TAT protein]; cypermethrin inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; Diethylnitrosamine inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]; Hydrocortisone promotes the reaction [[NR3C1 protein binds to TAT promoter] which results in increased expression of TAT mRNA]; Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; Methyldimethylaminoazobenzene inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]
CTD PMID:6120038 PMID:16267830 PMID:22465009 PMID:26647222 NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
JBrowse link
G Tbx19 T-box transcription factor 19 decreases abundance ISO TBX19 gene mutant form results in decreased abundance of Hydrocortisone CTD PMID:16390921 NCBI chr13:77,450,848...77,484,475
Ensembl chr13:77,450,849...77,504,163
JBrowse link
G Tbx2 T-box transcription factor 2 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA CTD PMID:34480604 NCBI chr10:70,679,670...70,688,868
Ensembl chr10:70,679,518...70,688,529
JBrowse link
G Tf transferrin multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; rosemarinic acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; rosemarinic acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] CTD PMID:33476690 PMID:34480604 NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
JBrowse link
G Tfap2a transcription factor AP-2 alpha multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA CTD PMID:34480604 NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
JBrowse link
G Tfap2b transcription factor AP-2 beta multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA CTD PMID:34480604 NCBI chr 9:21,786,250...21,815,785
Ensembl chr 9:21,786,258...21,814,520
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP
ISO
Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA
CTD PMID:17434272 PMID:33476690 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tgm1 transglutaminase 1 multiple interactions
increases expression
ISO [Hydrocortisone co-treated with sodium arsenate] results in increased expression of TGM1 mRNA; [Hydrocortisone co-treated with sodium arsenite] results in increased expression of TGM1 mRNA; sodium arsenate inhibits the reaction [Hydrocortisone results in increased expression of TGM1 mRNA]; sodium arsenite inhibits the reaction [Hydrocortisone results in increased expression of TGM1 mRNA] CTD PMID:11485391 NCBI chr15:29,191,039...29,206,000
Ensembl chr15:29,191,041...29,204,523
JBrowse link
G Tjp1 tight junction protein 1 increases localization
multiple interactions
ISO Hydrocortisone results in increased localization of TJP1 protein
GGTI 298 inhibits the reaction [Hydrocortisone results in increased localization of TJP1 protein]
CTD PMID:25763180 NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
JBrowse link
G Tlr2 toll-like receptor 2 increases expression ISO Hydrocortisone results in increased expression of TLR2 mRNA CTD PMID:17033190 NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
JBrowse link
G Tlr4 toll-like receptor 4 decreases expression ISO Hydrocortisone results in decreased expression of TLR4 mRNA CTD PMID:17033190 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
JBrowse link
G Tm4sf4 transmembrane 4 L six family member 4 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA CTD PMID:34480604 NCBI chr 2:141,570,321...141,621,263
Ensembl chr 2:141,481,902...141,621,200
JBrowse link
G Tnf tumor necrosis factor decreases secretion
multiple interactions
decreases expression
ISO Hydrocortisone results in decreased secretion of TNF protein
Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the expression of TNF mRNA]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
Hydrocortisone results in decreased expression of TNF mRNA
CTD PMID:9150321 PMID:10100995 PMID:15086553 PMID:21980503 PMID:26481333 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Treh trehalase decreases activity ISO Hydrocortisone results in decreased activity of TREH protein CTD PMID:2751871 NCBI chr 8:44,990,182...45,003,881
Ensembl chr 8:44,990,182...45,003,540
JBrowse link
G Tsc22d3 TSC22 domain family, member 3 multiple interactions
increases expression
ISO Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]
3-phenoxybenzoic acid inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [barium chloride results in increased abundance of Barium] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [cobaltous chloride results in increased abundance of Cobalt] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [cupric chloride results in increased abundance of Copper] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [lead nitrate results in increased abundance of Lead] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [Lithium Chloride results in increased abundance of Lithium] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [stannous chloride results in increased abundance of Tin] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [zinc chloride results in increased abundance of Zinc] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; cyhalothrin inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; DDT inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; resmethrin inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]
CTD PMID:25763180 PMID:26647222 PMID:29957541 NCBI chr  X:104,217,898...104,277,935
Ensembl chr  X:104,217,925...104,276,861
JBrowse link
G Ttr transthyretin multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA CTD PMID:34480604 NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA CTD PMID:34480604 NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
JBrowse link
G Ucn2 urocortin 2 increases abundance ISO UCN2 protein results in increased abundance of Hydrocortisone CTD PMID:16330704 NCBI chr 8:109,637,624...109,639,173
Ensembl chr 8:109,638,285...109,639,172
JBrowse link
G Ucp1 uncoupling protein 1 multiple interactions ISO [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] CTD PMID:33476690 NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
JBrowse link
G Ugt2a3 UDP glucuronosyltransferase family 2 member A3 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA CTD PMID:34480604 NCBI chr14:20,572,825...20,590,295
Ensembl chr14:20,572,808...20,590,729
JBrowse link
G Ugt2b17 UDP glucuronosyltransferase family 2 member B17 increases expression EXP Hydrocortisone results in increased expression of UGT2B1 mRNA CTD PMID:10476907 NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]] CTD PMID:10100995 PMID:15358673 PMID:34480604 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases expression
ISO Hydrocortisone inhibits the reaction [Nickel results in increased expression of VEGFA protein]
Hydrocortisone results in decreased expression of VEGFA protein
CTD PMID:9390328 PMID:17549480 PMID:20116850 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Vgll1 vestigial-like family member 1 multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA CTD PMID:34480604 NCBI chr  X:134,979,657...134,996,007 JBrowse link
G Vwf von Willebrand factor multiple interactions
increases expression
ISO Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of VWF mRNA] CTD PMID:25763180 NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
JBrowse link
G Zfand2a zinc finger AN1-type containing 2A multiple interactions ISO [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA CTD PMID:34480604 NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677
JBrowse link
G Zfp36 zinc finger protein 36 increases expression ISO Hydrocortisone results in increased expression of ZFP36 mRNA CTD PMID:21980503 NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564
JBrowse link
hydrocortisone succinate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [hydrocortisone hemisuccinate co-treated with Dimethyl Sulfoxide] results in increased expression of CYP1A2 CTD PMID:18347083 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO [hydrocortisone hemisuccinate co-treated with Dimethyl Sulfoxide] results in increased expression of CYP3A4 CTD PMID:18347083 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G F2 coagulation factor II affects expression ISO hydrocortisone hemisuccinate affects the expression of F2 protein CTD PMID:12542493 NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
JBrowse link
G Il18 interleukin 18 decreases secretion ISO hydrocortisone hemisuccinate results in decreased secretion of IL18 protein CTD PMID:20421217 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
JBrowse link
G Il1b interleukin 1 beta decreases secretion ISO hydrocortisone hemisuccinate results in decreased secretion of IL1B protein CTD PMID:20421217 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 decreases secretion ISO hydrocortisone hemisuccinate results in decreased secretion of IL6 protein CTD PMID:20421217 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Tnf tumor necrosis factor decreases secretion ISO hydrocortisone hemisuccinate results in decreased secretion of TNF protein CTD PMID:20421217 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20072
    chemical entity 20071
      atom 20071
        nonmetal atom 19963
          carbon atom 19896
            organic molecular entity 19896
              lipid 17772
                steroid 14393
                  C21-steroid 3995
                    17alpha-hydroxy-C21-steroid 277
                      17alpha-hydroxypregn-5-ene-3,20-dione 0
                      17alpha-hydroxypregnenolone + 1
                      17alpha-hydroxyprogesterone 13
                      20beta-dihydrocortisol 0
                      21-deoxycortisol 0
                      5beta-dihydrocortisol 0
                      cortisol + 273
Path 2
Term Annotations click to browse term
  CHEBI ontology 20072
    subatomic particle 20071
      composite particle 20071
        hadron 20071
          baryon 20071
            nucleon 20071
              atomic nucleus 20071
                atom 20071
                  main group element atom 19974
                    p-block element atom 19974
                      carbon group element atom 19903
                        carbon atom 19896
                          organic molecular entity 19896
                            organic molecule 19844
                              organic cyclic compound 19605
                                organic polycyclic compound 17197
                                  steroid 14393
                                    hydroxy steroid 14108
                                      17-hydroxy steroid 13776
                                        17alpha-hydroxy steroid 5407
                                          17alpha-hydroxy-C21-steroid 277
                                            17alpha-hydroxypregn-5-ene-3,20-dione 0
                                            17alpha-hydroxypregnenolone + 1
                                            17alpha-hydroxyprogesterone 13
                                            20beta-dihydrocortisol 0
                                            21-deoxycortisol 0
                                            5beta-dihydrocortisol 0
                                            cortisol + 273
paths to the root